These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 31541198)
21. Immunological Approaches to Tumor Therapy. Proceedings from the III International Meeting on Idiotypic Network and Tumor Therapy by Gene Therapy, Drug Targeting, Vaccination, and Photodynamic Therapy. Bonn, Germany, February 29-March 2, 1996. Hybridoma; 1997 Feb; 16(1):1-137. PubMed ID: 9273346 [No Abstract] [Full Text] [Related]
22. Immuno-oncology for surgeons. Lee SL; Al-Shamkhani A; Mirnezami A Br J Surg; 2019 Sep; 106(10):1273-1282. PubMed ID: 31318438 [TBL] [Abstract][Full Text] [Related]
23. AACR Cancer Progress Report 2016. Davidson NE; Armstrong SA; Coussens LM; Cruz-Correa MR; DeBerardinis RJ; Doroshow JH; Foti M; Hwu P; Kensler TW; Morrow M; Mulligan CG; Pao W; Platz EA; Smith TJ; Willman CL Clin Cancer Res; 2016 Oct; 22 Suppl 19():S1-S137. PubMed ID: 27697776 [No Abstract] [Full Text] [Related]
24. Trends and challenges in immuno-oncology trials. Kiernan B Drugs Today (Barc); 2016 Jul; 52(7):387-93. PubMed ID: 27540597 [TBL] [Abstract][Full Text] [Related]
25. Cancer Nanomedicine: Lessons for Immuno-Oncology. Sengupta S Trends Cancer; 2017 Aug; 3(8):551-560. PubMed ID: 28780932 [TBL] [Abstract][Full Text] [Related]
26. Future shock: embracing disruption in the immunotherapy revolution. Alvarnas J Am J Manag Care; 2018 Feb; 24(2 Spec No.):SP34. PubMed ID: 29689140 [No Abstract] [Full Text] [Related]
27. [A special issue dedicated to immuno-oncology]. Bibeau F; Badoual C Ann Pathol; 2017 Feb; 37(1):1-2. PubMed ID: 28109693 [No Abstract] [Full Text] [Related]
28. Advanced APMs and the emerging role of immuno-oncology agents: balancing innovation and value. Seiden MV; Neubauer M; Verrilli D Am J Manag Care; 2017 Feb; 23(2 Spec No.):SP69-SP77. PubMed ID: 28298130 [No Abstract] [Full Text] [Related]
29. [Which future for B lymphocytes infiltrating solid tumors: prognostic biomarker and/or therapeutic target?]. Kaplon H; Dieu-Nosjean MC Med Sci (Paris); 2018 Jan; 34(1):72-78. PubMed ID: 29384099 [TBL] [Abstract][Full Text] [Related]
33. [Evolution and revolution in systemic treatment of lung cancer. The new role of immunotherapy]. Duruisseaux M; Berghmans T Rev Mal Respir; 2018 Feb; 35(2):101-102. PubMed ID: 29548518 [No Abstract] [Full Text] [Related]
34. [Advances in medical oncology]. Shi YK Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Jun; 28(3):305-10. PubMed ID: 16900620 [TBL] [Abstract][Full Text] [Related]
35. [Oncology 1999: advances in immunotherapy]. Cerny T Schweiz Med Wochenschr; 2000 Jan; 130(1-2):21-4. PubMed ID: 10670041 [No Abstract] [Full Text] [Related]
36. Forty-five years in oncology, 25 years with Acta Oncologica. Glimelius B Acta Oncol; 2018 Dec; 57(12):1593-1598. PubMed ID: 30489167 [No Abstract] [Full Text] [Related]
37. The changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in Oncology & Hemato-Oncology (ICTO 2017). Golan T; Milella M; Ackerstein A; Berger R J Exp Clin Cancer Res; 2017 Dec; 36(1):192. PubMed ID: 29282151 [TBL] [Abstract][Full Text] [Related]
38. Emerging Immunotherapies for Cancer and Their Potential for Application in Pediatric Oncology. Orentas RJ; Mackall CL Crit Rev Oncog; 2015; 20(3-4):315-27. PubMed ID: 26349422 [TBL] [Abstract][Full Text] [Related]
39. Immuno-oncology and Its Opportunities for Interventional Radiologists: Immune Checkpoint Inhibition and Potential Synergies with Interventional Oncology Procedures. Hickey RM; Kulik LM; Nimeiri H; Kalyan A; Kircher S; Desai K; Riaz A; Lewandowski RJ; Salem R J Vasc Interv Radiol; 2017 Nov; 28(11):1487-1494. PubMed ID: 28912090 [TBL] [Abstract][Full Text] [Related]